Northstrive Biosciences Inc., a subsidiary of PMGC Holdings Inc., announced on February 18, 2025, the successful submission of a pre-Investigational New Drug (pre-IND) meeting request to the U.S. Food and Drug Administration (FDA) for EL-22.
EL-22 is a novel myostatin asset aimed at preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. This submission is a crucial step in advancing the drug candidate towards clinical development.
A pre-IND meeting with the FDA is expected in Q2 2025 to discuss nonclinical studies and Northstrive Biosciences’ clinical development plans for EL-22. The company aims to evaluate EL-22 administered in combination with GLP-1 receptor agonists in obese patients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.